NCT07589634
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07589634
Title A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma (TRI Pro)
Acronym TRI Pro
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Beverly Hills Cancer Center (BHCC) RECRUITING Beverly Hills California 90211 United States Details
Hospital Ampang RECRUITING Ampang 68000 Malaysia Details
Hospital Sultanah Aminah RECRUITING Johor Bharu 80100 Malaysia Details
Sarawak General Hospital RECRUITING Kuching 93586 Malaysia Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field